The cause of compensatory hyperinsulinemia in normoglycemic insulin-resistant states is unknown. Using spontaneously hypertensive rats (SHR), we tested the hypothesis that a lowered a8-cell set-point for glucose causes a hypersecretion of insulin at a normal glucose level. Islets isolated from normoglycemic hyperinsulinemic SHR were compared to age-matched (12 wk old) Wistar-Kyoto (WK) rats. The ED5. for glucose-induced insulin secretion was 6.6±1.0 mM glucose in SHR versus 9.6±0.5 mM glucose in WK (P < 0.02). Glucokinase enzymatic activity was increased 40%
Introduction
The islet /l-cell precisely maintains the blood glucose level through a feedback loop between the level of blood glucose and insulin secretion (1) . As such, changes in insulin secretion are presumed to occur secondary to fluctuations in glycemia. However, states of insulin resistance such as obesity (2, 3) are characterized by normal blood glucose levels and an increase in insulin secretion (4) . The mechanism of the /3-cell hyperfunction in euglycemic insulin resistant states is unexplained.
Studies in insulin-resistant rat models have suggested a mechanism. The LAN-cp rats, Zucker fatty rats, and pregnant rats, all have lowered set-points for glucose-induced insulin secretion (5-8) which could explain exaggerated insulin output at a normal glucose level. However, none of the previous studies characterized the plasma glucose levels carefully, and hyperglycemia is known to shift the glucose concentration-insulin secretion curve to the left (9) (10) (11) (12) (13) (14) (15) . We examined rats that were hyperinsulinemic and normoglycemic after a 48-h iv glucose infusion to identify the mechanism for their hypersecretion of insulin ( 16) . The hyperinsulinemia was associated with a lowered setpoint for glucose-induced insulin secretion, and an increased islet glucokinase activity, which reinforces the role of this important enzyme in regulating the f6-cell glucose sensitivity ( 17) . Surprisingly, the glucokinase protein level was not increased. Thus, glucokinase in the /3-cell appears to be regulated not only by the previously known effect of the plasma glucose level to control its cellular content ( 17, 18) , but also through altering the activity of the enzyme. However, the relevance of our previous studies to euglycemic insulin resistant states was unclear because in the animal model we used (48-h glucose infusions), the rats were hyperglycemic during the first 6 h of the infusion ( 16) .
We now have investigated the basis for compensatory hyperinsulinemia in spontaneously hypertensive rats (SHR).' Of key importance, these insulin resistant rats ( 19, 20) are normoglycemic, even when challenged with oral or intravenous glucose (21, 22) . We hypothesized that SHR would be hyperinsulinemic because of a shift in the glucose concentration-insulin secretion relationship to lower glucose levels, and that the mechanism would be an increase in the catalytic activity of the key /3-cell "glucose sensor" enzyme, glucokinase. in 5% nonfat dry milk, 0.01% Tween 20, 20 mM Tris/HCl, pH 7.4, then incubated at room temperature with the specific antisera. Glucokinase: ( 1 ) sheep antiserum raised against an E. coli-derived B I isoform of rat glucokinase (gift from Dr. Mark Magnuson, Vanderbilt University, Nashville, TN) at 1:500 dilution for 3 h, (2) rabbit anti-sheep IgG (Sigma Chemical Co.) at 1:1,500 dilution for 1 h. GLUT-2: rabbit antiserum raised against a polypeptide that corresponded to amino acids 513-522 of rat GLUT-2 (gift from Dr. Bernard Thorens, Lausanne, Switzerland) at 1:100 dilution for 2 h. Bound antibody was detected with "I-conjugated protein A (ICN, Costa Mesa, CA). Band intensity was quantified by densitometry using IMAGE 1.4 software (NIH, Bethesda, MD). Extracts were used for glucokinase and GLUT-2 only once so that the "n" cited in the text is the number of rats studied.
Methods
Analytical methods. Plasma glucose was measured with a Beckman Glucose Analyzer II (Beckman Instruments, Inc., Fullerton, CA). The insulin RIA used charcoal separation (24) and rat insulin standards (Lilly, Indianapolis, IN).
Data presentation and statistical methods. All data are expressed as mean±SEM. The listed "n" in all experiments is the number of rats studied. The densitometry results from the Western blots are expressed in relative terms by comparing the SHR extract on each gel to the WK extract (assigned a value of 100%). Statistical significance was determined by the unpaired Student's t test. The one-way t-test was used for the Western blot results.
Results
General characteristics of SHR rats (Table I ). The body weights of 12-wk-old SHR rats were lower than age-matched WK rats. Insulin resistance was confirmed by the twofold higher basal plasma insulin level (P < 0.0015) in conjunction with a normal plasma glucose. To further characterize the plasma glucose level of SHR, an OGTT and a meal challenge were performed. An (Fig.  1) . Similar results were obtained during the meal challenge.
Insulin secretion. Insulin secretion was measured at varying glucose concentrations in islets isolated from SHR and WK rats (Fig. 2) . The curve in the WK islets was sigmoidal with a half maximal insulin response (ED50) of 9.6+0.5 mM glucose versus 6.6±1.0 mM glucose in SHR (P < 0.02) without any change in the maximal response. At 8.3 mM glucose (reproducing the basal plasma glucose level of both groups), insulin secretion from SHR was twice that of WK ( 15.2±1.8 ng/10 islets versus 8.7±1.8 ng/10 islets WK, P < 0.031).
Glucose utilization. The glucose concentration-glucose utilization curve was also shifted to the left in SHR (Fig. 3) . However, the pattern differed from that for insulin secretion. Glucose utilization was 20-40% higher in the SHR islets at all glucose concentrations including 27.7 mM (215±12 pmol glucose/90 min/islet versus 169±11 pmol glucose/90 min/ islet WK, P < 0.019). As Fig. 4 . The DNA contents of the SHR and WK islets were the same, as were the V., and Km values for hexokinase. In contrast, the glucokinase V.. was increased 40% in SHR (P < 0.02) without any change in the Km.
Islet glucokinase and GLUT-2 protein levels. The etiology of the increased glucokinase Vma,, was investigated by quantifying the protein level of glucokinase by Western blot (Fig. 5) . A total of seven SHR and WK rats were studied. Single bands at 52 kD characteristic of glucokinase were found in both groups. Identical levels of glucokinase were found in the SHR and WK islets (SHR 95+±3% of WK). It has recently been speculated that the level of the ,8-cell glucose transporter, GLUT-2, affects glucokinase activity (32) . Therefore, GLUT-2 was also quantified in SHR and WK islets (Fig. 6) . A total of 10 WK and SHR rats were studied. The GLUT-2 band was located at 55 kD in both groups. Its level was raised in SHR islets to 176±31% of WK (P < 0.036).
Discussion
Glucose phosphorylation by glucokinase plays a central role in determining the /i-cell sensitivity to glucose (17, 18) . Our finding of an augmented catalytic activity of this enzyme in SHR islets expands the understanding of how this /-cell "glucose sensor" is regulated. It is well-known that the /3-cell content of glucokinase is modulated by the plasma glucose level (16) (17) (18) . We have identified an additional level of control through alterations in the catalytic activity. Supporting this idea, we made a similar observation in normoglycemic glucose-infused rats (16) . Also, Iynedjian et al. (33) observed no change in the level of glucokinase in islets from 72-h fasted rats despite a reported 30% reduction in glucokinase activity (34) . Importantly, in both of our studies, this effect was noted in normoglycemic rats. Thus, sustained changes in plasma glucose are not required to mediate the effect on glucose sensing. These data provide a mechanism for compensatory adaptions of insulin secretion under normoglycemic conditions.
Potential cellular mechanisms by which the catalytic activity of glucokinase could be altered have received recent attention. Malaisse et al. (35) i.e., the pattern found in the SHR islets. Our intriguing finding of the increased GLUT-2 level in SHR islets may provide additional support for this idea although coincidental occurrences clearly cannot be ruled out.
The concept that glucokinase activity determines the /3-cell sensitivity to glucose is based on the understanding that glucosestimulated insulin secretion is dependent on /3-cell glucose metabolism, and that glucokinase is the rate-limiting step (17) . Why then were the patterns for insulin secretion and glucokinase activity different in the SHR islets: a lowered EDm in the secretion curve without a change in V,,, versus an increased V..
for glucokinase without a change in Km? We have postulated that the maximal limit for glucose-stimulated insulin secretion is set by a factor other than /3-cell glucose metabolism (16) .
In that case, an increase in glucokinase activity would enhance insulin output at submaximal levels of glucose without changing the maximal insulin response. The glucose utilization data support this suggestion, since in SHR the curve for glucose utilization matched that of phosphorylation. These data suggest that insulin secretion is uncoupled from /-cell glucose metabolism at high glucose concentrations which explains the lack of an increase in maximal glucose-induced insulin secretion in SHR islets.
An important caveat is to determine if the functional changes in SHR are real, or if there are dissimilar masses of /3-cells in the SHR and WK islets. This analysis is particularly important, since insulin resistance causes a compensatory increase in pancreatic /-cell mass (39) . For unclear reasons, this effect apparently does not occur in SHR. A morphometric study in pancreases from 4-mo-old SHR and WK rats found identically sized islets with the same proportions of insulin, glucagon, and somatostatin containing cells (40) . Also, two findings in this study are consistent with a similar /3-cell mass in SHR and WK islets: identical islet DNA content and identical maximal insulin response to glucose.
In summary, the insulin-resistant SHR rats were hyperinsulinemic because of an increase in the /-cell sensitivity for glucose due to an augmented catalytic activity of glucokinase, which in turn may be regulated by the /6-cell glucose transporter. These findings provide a mechanism for /-cell hyperfunction in the presence of normoglycemia.
